
IGC Stock Forecast & Price Target
IGC Analyst Ratings
Bulls say
IGC Pharma is a clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies for the treatment of Alzheimer's disease (AD). With 5 novel drug candidates targeting AD, including two in later stages of development and promising data from its ongoing CALMA clinical trial, the company has a positive outlook. Additionally, the recent change in fiscal year and upcoming milestones, including the completion of the CALMA trial and release of its AI beta program, could serve as catalysts for the stock. Despite potential risks, such as balance sheet and liquidity concerns, the company has significant market potential as there are currently no known cures or effective treatments for AD, a leading cause of dementia impacting millions of Americans.
Bears say
IGC Pharma is facing significant risks in achieving its goal, including balance sheet and liquidity risks, failure of product candidates in clinical trials, and challenges in gaining regulatory approval and commercialization. While the company has 5 drug candidates for Alzheimer's disease, its current valuation is primarily based on a single drug, IGC-AD1, which is still in clinical trials and may not be successful in addressing agitation in dementia. There are also concerns about competition and changing macroeconomic factors, making the stock a high-risk investment with uncertain upside potential.
This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.
IGC Analyst Forecast & Price Prediction
Start investing in IGC
Order type
Buy in
Order amount
Est. shares
0 shares